65 related articles for article (PubMed ID: 26022650)
1. Two Cases of Successful Autologous Hematopoietic Stem Cell Harvest after Treatment with Brentuximab Vedotin.
Kojima M; Ogiya D; Kawai H; Miyamoto M; Ohmachi K; Ogawa Y; Nakamura N; Ando K
Acta Haematol; 2015; 134(3):181-2. PubMed ID: 26022650
[No Abstract] [Full Text] [Related]
2. Hodgkin lymphoma treatment for older persons in the modern era.
Evens AM; McKenna M; Ryu Tiger YK; Upshaw JN
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):483-499. PubMed ID: 38066840
[TBL] [Abstract][Full Text] [Related]
3. Toward a cure for cHL without chemotherapy.
Lynch RC
Blood; 2024 Feb; 143(9):741-742. PubMed ID: 38421817
[No Abstract] [Full Text] [Related]
4. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.
Chen R; Palmer JM; Martin P; Tsai N; Kim Y; Chen BT; Popplewell L; Siddiqi T; Thomas SH; Mott M; Sahebi F; Armenian S; Leonard J; Nademanee A; Forman SJ
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2136-2140. PubMed ID: 26211987
[TBL] [Abstract][Full Text] [Related]
5. Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens.
Niesvizky R; Flinn IW; Rifkin R; Gabrail N; Charu V; Clowney B; Essell J; Gaffar Y; Warr T; Neuwirth R; Zhu Y; Elliott J; Esseltine DL; Niculescu L; Reeves J
J Clin Oncol; 2015 Nov; 33(33):3921-9. PubMed ID: 26056177
[TBL] [Abstract][Full Text] [Related]
6. Panitumumab after progression on cetuximab in KRAS wild-type metastatic colorectal cancer patients: a single institution experience.
Marino A; Caliolo C; Sponziello F; Nacci A; Quaranta A; Mazzoni E; Lutrino SE; Rizzo P; Calvani N; Orlando L; Schiavone P; Fedele P; D'Amico M; Chetrì MC; Cinefra M; Ferrara P; Cinieri S
Tumori; 2015; 101(5):524-8. PubMed ID: 26045117
[TBL] [Abstract][Full Text] [Related]
7. The new therapeutical scenario of Hodgkin lymphoma.
Stathis A; Younes A
Ann Oncol; 2015 Oct; 26(10):2026-33. PubMed ID: 26037796
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib-based therapy for mantle-cell lymphoma.
Sengar M; Jain H
N Engl J Med; 2015 Jun; 372(23):2270-1. PubMed ID: 26039614
[No Abstract] [Full Text] [Related]
9. First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis.
Pietrantonio F; Cremolini C; Petrelli F; Di Bartolomeo M; Loupakis F; Maggi C; Antoniotti C; de Braud F; Falcone A; Iacovelli R
Crit Rev Oncol Hematol; 2015 Oct; 96(1):156-66. PubMed ID: 26088456
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib: A Review in Mantle Cell Lymphoma in Previously Untreated Patients Unsuitable for Stem-Cell Transplantation.
McCormack PL
BioDrugs; 2015 Jun; 29(3):207-14. PubMed ID: 26115634
[TBL] [Abstract][Full Text] [Related]
11. Brentuximab Vedotin in CD30-Positive Lymphomas: A SIE, SIES, and GITMO Position Paper.
Zinzani PL; Corradini P; Gianni AM; Federico M; Santoro A; Vitolo U; Barosi G; Tura S
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):507-13. PubMed ID: 26195435
[TBL] [Abstract][Full Text] [Related]
12. The importance of optimal drug sequencing in metastatic colorectal cancer: biological rationales for the observed survival benefit conferred by first-line treatment with EGFR inhibitors.
Wainberg ZA; Drakaki A
Expert Opin Biol Ther; 2015; 15(8):1205-20. PubMed ID: 26066903
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic versus reactive treatment of acneiform skin rashes from epidermal growth factor receptor inhibitors in metastatic colorectal cancer.
Dascalu B; Kennecke HF; Lim HJ; Renouf DJ; Ruan JY; Chang JT; Cheung WY
Support Care Cancer; 2016 Feb; 24(2):799-805. PubMed ID: 26184500
[TBL] [Abstract][Full Text] [Related]
14. Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC).
Heinemann V; Stintzing S; Modest DP; Giessen-Jung C; Michl M; Mansmann UR
Eur J Cancer; 2015 Sep; 51(14):1927-36. PubMed ID: 26188850
[TBL] [Abstract][Full Text] [Related]
15. Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.
Martino M; Festuccia M; Fedele R; Console G; Cimminiello M; Gavarotti P; Bruno B
Expert Opin Biol Ther; 2016; 16(3):347-64. PubMed ID: 26652934
[TBL] [Abstract][Full Text] [Related]
16. STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer.
Chibaudel B; Bonnetain F; Tournigand C; de Larauze MH; de Gramont A; Laurent-Puig P; Paget J; Hadengue A; Notelet D; Benetkiewicz M; André T; de Gramont A
BMC Cancer; 2015 Jul; 15():496. PubMed ID: 26141683
[TBL] [Abstract][Full Text] [Related]
17. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Dimopoulos MA; Moreau P; Palumbo A; Joshua D; Pour L; Hájek R; Facon T; Ludwig H; Oriol A; Goldschmidt H; Rosiñol L; Straub J; Suvorov A; Araujo C; Rimashevskaya E; Pika T; Gaidano G; Weisel K; Goranova-Marinova V; Schwarer A; Minuk L; Masszi T; Karamanesht I; Offidani M; Hungria V; Spencer A; Orlowski RZ; Gillenwater HH; Mohamed N; Feng S; Chng WJ;
Lancet Oncol; 2016 Jan; 17(1):27-38. PubMed ID: 26671818
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma.
Broijl A; Kersten MJ; Alemayehu WG; Levin MD; de Weerdt O; Vellenga E; Meijer E; Wittebol S; Tanis BC; Cornelisse PB; Stevens-Kroef M; Bos GM; Wijermans PW; Lokhorst H; Sonneveld P
Haematologica; 2016 Apr; 101(4):e149-52. PubMed ID: 26659914
[No Abstract] [Full Text] [Related]
19. Maintenance therapy for multiple myeloma in the era of novel agents.
Facon T
Hematology Am Soc Hematol Educ Program; 2015; 2015():279-85. PubMed ID: 26637734
[TBL] [Abstract][Full Text] [Related]
20. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment.
Richardson PG; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Guenther A; Nakorn TN; Siritanaratkul N; Schlossman RL; Hou J; Moreau P; Lonial S; Lee JH; Einsele H; Sopala M; Bengoudifa BR; Corrado C; Binlich F; San-Miguel JF
Blood; 2016 Feb; 127(6):713-21. PubMed ID: 26631116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
